EXHIBITOR GUIDE

ARS 67th Annual Meeting

October 1-2, 2021 | Millennium Biltmore Hotel, Los Angeles, CA
On behalf of the American Rhinologic Society, it is my pleasure to welcome you to Los Angeles and the 67th ARS Annual Meeting. In July, we had a successful and well-attended in-person Summer Sinus Symposium in Austin despite the persistent pandemic. The American Rhinologic Society is committed to providing first class educational meetings and materials for our members, and I am confident that you will be very pleased with our Annual Meeting program. I want to recognize and thank Rodney Schlosser, the President-Elect and Program Chair, along with the program committee who have put together a fantastic scientific program that features the best scientific abstracts, interesting keynote speakers, and several informative and clinically relevant panels. Also, a very special thank you to Wendi, Susan, and Tammy for their tirelessly work behind the scenes, during these challenging times that continue to be ever-changing.

During these difficult times, we have become more aware and appreciative of the blessings we have in our lives. I want to thank all our ARS members for your continued support during this unusual time the past couple of years. I would also like to acknowledge and thank our many corporate sponsors who have continued to generously support our society that is focused on rhinologic, allergic, and skull base diseases. Without their partnership, we would not be able to bring such high quality virtual and in-person meetings for our members. During our meetings, please visit them in the exhibit hall to express our appreciation for their support.

With the arrival of our annual meeting, my presidency is coming to an end. It has been an honor and pleasure to serve our wonderful society. We have a wonderful group of volunteer physicians that make our society great. Also, our society provides an environment full of friendship and camaraderie as well as provide a platform for discussing the most up to date scientific information. The current tough times will pass, and I am certain our organization will continue to achieve enormous things in the future. I want to thank you for the chance to serve as a steward of such a wonderful organization.

I look forward to seeing you in Los Angeles!

Joseph K Han, MD, FARS
President, American Rhinologic Society
Welcome from the Program Chair

Join us!

Shake off the COVID blues as the American Rhinologic Society plans to resume IN PERSON gatherings at our Annual Meeting in Los Angeles this October! We have a great program planned and the highlight of the meeting will be TWO David W. Kennedy Lecturers....

In honor of David’s retirement from operating, we are pleased to announce that he will be giving a keynote address reflecting upon more than three decades of experience in the world of rhinology. We will also be joined by Louis Shipley for our 2nd Kennedy Keynote Lecture. Louis is a technology CEO and lecturer at Harvard Business School and MIT Sloan School of Management. He will be discussing “Leveraging disruptive technology in a post-pandemic world”.

Our wide variety of panels will include an ARS/ AAOA panel on the Burden of rising healthcare costs – A case study of CRSwNP, Role of the rhinologist in sleep disorders, Rhinology worldwide, Building a successful rhinology practice, Digital patient engagement, and Omics and biomarkers: Impact upon patient care. This year we welcome our Guest Countries’ colleagues from South Korea. In addition, the ARS’ welcomes the AAO-HNS’ Guest Countries, Poland, Ghana, Australia, Brazil, and New Zealand. All of this is in addition to the many original research presentations that we are used to seeing at ARS meetings. Please come out and enjoy the company of your fellow rhinologists! As part of this specialty-wide celebration, the Academy will be holding a Combined President’s Reception this year, on Saturday night October 2nd, which will be co-hosted by the Presidents of the Academy, ARS, AOS, and ANS. We are honored and pleased to join the AAO-HNS for this event. AAO-HNS Meeting registrants will receive an event ticket with their paid registration. The ARS is pleased to offer significantly discounted tickets to the Red Carpet Event via the ARS registration page. There is no limit on ticket purchases. Registration and Housing are now OPEN. On behalf of myself, the Program Committee, and the Board of Directors, we are looking forward to seeing you in Los Angeles. Additional questions, please contact our Executive Administrator, Wendi Perez at Wendi@american-rhinologic.org or 973-545-2735.

Thank you.

Rodney Schlosser, MD, FARS
President-Elect/Program Chair
Welcome from the Executive Vice President

Thank you for your support of the ARS during these challenging times. All ARS members should be very proud of the remarkable efforts of so many of our members and leaders to continue the mission of the Society.

I want to recognize ARS President Joseph Han, MD, and ARS President-Elect and Program Chair Rodney Schlosser, MD, who have done tremendous work to keep the Society on track and to allow us to hold the 67th Annual Meeting live and in person in Los Angeles. The ARS actually hosted, this summer, perhaps the first significant in-person meeting in our specialty since the pandemic started, with the Summer Sinus Symposium in Austin, TX. The course co-directors – Drs. Greg Davis, Marc Dubin and Doug Reh – did an amazing job of coordination and management and we had a very successful meeting with great education and great fellowship, and no Covid related issues. Also of course our ARS Administrative Staff of Wendi Perez, Susan Arias and Tammy Lorimer are indispensable to the Society as well!

This year’s meeting program contains a rich combination of new research, invited lectures and panel discussions, and we are excited to bring it to you.

Welcome to Los Angeles and I hope you enjoy the 67th Annual Meeting!

Michael G. Stewart, MD, MPH, FARS
Executive Vice President
ARS 67th Annual Meeting Industry Supporters

The American Rhinologic Society gratefully acknowledges the following companies for their support of the 67th Annual Meeting

GSK
Gold Sponsor

Sanofi Genzyme and Regeneron
Medtronic
Silver Sponsor

KARL STORZ Endoscopy, America, Inc.
Bronze Sponsor

Acclarent
Medtronic
Olympus America Inc.
Grant Support

Medtronic
David W. Kennedy Lecture
David Kennedy Reception

Olympus America Inc.
Residents Dissection Lab

Intersect ENT
Residents Reception

Stryker
Women in Rhinology/Mentorship/
Residents & Fellows Program

KARL STORZ Endoscopy, America, Inc.
17th Annual David W. Kennedy Lectureship

Exhibitors

3-D Matrix, Inc.
Acclarent
Advanced RX Compounding
Pharmacy
Aerin Medical
ALK-Abelló, Inc.
C2Dx

GSK
Hemostasis, LLC
Intersect ENT
KARL STORZ Endoscopy-
America, Inc.
Medtronic
Modernizing Medicine

MicroGenDX
NeilMed Pharmaceuticals
Olympus America Inc.
Optinose
Sanofi Genzyme & Regeneron
Stryker ENT
Xoran Technologies
Floor Plan

Meeting Room Locations

Mezzanine Level/Main Galleria Level

Main Galleria Level

Biltmore Bowl Level/South Galleria

Regency Level/South Galleria

Athenian
Corinthian
Corsican
Florentine
Grecian
Mediterranean
Moroccan
Roman

Crystal
Emerald
Gold
Heinsbergen
Tiffany

Biltmore Bowl
Industry Sessions

Friday, October 1, 2021

12:00 pm – 12:50 pm
**Acclarent Lunch Symposium**
**Location:** Heinsbergen Room
**Title:** “AI in ENT – The Role of Navigation in Surgical Training”
**Speakers:** Troy Woodard, MD, FARS; Raj Sindwani, MD, FARS; James Palmer, MD, FARS; Nithin Adappa, MD, FARS

*This is a non-CME event sponsored by Acclarent. It is neither sponsored by nor endorsed by the ARS.*

12:00 pm – 12:50 pm
**GSK**
**Location:** Gold Room
**Title:** “Evidence for Use of a Biologic in the Management of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)”
**Description:** this program will review the clinical evidence for the use of a biologic, non-surgical treatment option in adult patients with CRSwNP. The presentation will concorporate a patient case and discuss the role of eosinophilic inflammation in recurrent nasal polyps.

**Speakers:** Christine Franzese, MD, FARS

*This is a non-CME event sponsored by GlaxoSmithKline. It is neither sponsored by, nor endorsed by, the ARS.*

Saturday, October 2, 2021

7:00 am – 7:50 am
**Optinose Breakfast Symposium**
**Location:** Gold Room
**Title:** “XHANCE: An Emerging Stepped-Care Paradigm for the Treatment of Nasal Polyps”
**Description:** Use a case basked approach to understand the efficacy and safety of XHANCE in the treatment of Nasal Polyps, and evaluate an emerging approach for stepped-care management of Nasal Polyps

**Speakers:** Joseph Han, MD, FARS

*This is a non-CME event sponsored by Optinose. It is neither sponsored by, nor endorsed by, the ARS.*

7:00 am – 7:50 am
**A Product Theater Sponsored by Sanofi Genzyme and Regeneron**
**Location:** Crystal Ballroom
**Title:** “Explore a Different Path to Control Chronic Rhinosinusitis With Nasal Polyposis in Your Patients With Inadequately Controlled Disease”
**Description:** Engage with our presenter as they discuss a treatment option for patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP). They will discuss the underlying Type 2 inflammation that contributes to the disease burden. The presenter will apply these concepts into their case-based review of a patient with CRSwNP.

**Speaker:** Jayant Pinto, MD

*This is a non-CME event sponsored by Sanofi Genzyme and Regeneron. It is neither sponsored by, nor endorsed by, the ARS.*
PROGRAM AT A GLANCE

Thursday, September 30, 2021

7:00 am – 1:00 pm
Residents Course – Didactic Session
Tiffany Ballroom
By Invitation Only

1:30 pm – 4:20 pm
Residents Dissection Lab
Emerald Ballroom
By Invitation Only

5:30 pm – 7:00 pm
Residents Reception
John F. Kennedy Penthouse

Friday, October 1, 2021

7:00 am – 1:00 pm
Board of Directors Breakfast
Emerald Ballroom

8:00 am – 12:00
Board of Directors Meeting
Emerald Ballroom

Friday, October 1, 2021

1:00 pm – 5:00 pm
General Session
Crystal Ballroom

1:00 pm - 1:15 pm
Presidential Address & Welcome
Joseph Han, MD, FARS

1:15 pm - 2:00 pm
17th Annual David W. Kennedy Lecture
Introduction: Rodney Schlosser, MD, FARS
Guest Speaker: N. Louis Shipley, Harvard Business School
“Leveraging disruptive technology in a post pandemic world”

2:00 pm - 2:15 pm
Awards Ceremony: Robert Kern, MD, FARS;
Benjamin Bleier, MD, FARS; Jivianne Lee, MD,
FARS; Jean Kim, MD, FARS

Top Clinical Abstracts

Moderators: Dana Crosby, MD, FARS; Jean Kim,
MD, FARS

2:15 pm - 2:22 pm
PK evidence of consistent drug release from long-
acting implantable corticosteroid matrices for CRS
Randall A. Ow, MD

2:22 pm - 2:29 pm
Outcomes of Dupilumab treatment versus FESS
for CRSwNP
Harish Dharmarajan, MD

2:29 pm - 2:36 pm
CRS-PRO and SNOT 22 correlations with type 2
inflammatory mediators in chronic rhinosinusitis
Samuel Racette, MD

2:36 pm - 2:43
Dupilumab and ASA desensitization CEA
Michael Yong, MD, MPH, MBA

2:43 pm - 2:50 pm
Predicting malignant transformation of inverted
papilloma using image-based machine learning
Angela Yang, BS

2:50 pm - 3:00 pm
Q&A

3:00 pm - 3:30 pm
BREAK

Top Basic Science Abstracts

Moderators: Stella Lee, MD; Cecelia Damask,
DO; Justin Turner, MD, FARS

3:30 pm - 3:37 pm
LPS decreases CFTR open probability and
mucociliary transport through ROS
Do-Yeon Cho, MD

3:37 pm - 3:44 pm
Transcriptional changes in chronic rhinosinusitis
with asthma
Amarbir Gill, MD

3:44 pm - 3:51 pm
Cystatin-induced coagulation and fibrinolysis
pathway derangements in a murine model of
CRSwNP
Alan Workman, MD, MTR

3:51 pm - 3:58 pm
Steroid responsive and steroid resistant cytokines
in AERD
Michael Kohanski, MD, PhD

3:58 pm - 4:05 pm
A human paranasal sinus model of SARS-CoV-2
infection
Wesley Stepp, MD, PhD

4:05 pm - 4:15 pm
Q&A

4:15 pm - 5:00 pm
Panel: “Lessons Learned: Reflections of
Seasoned Rhinologists”
Moderator: Eugenia Vining, MD
Panelists: Marilene Wang, MD, FARS; James
Stankiewicz, MD, FARS; Michael Setzen, MD,
FARS; Donald Lanza, MD, FARS

17th Annual David W. Kennedy Lecture
Introduction: Rodney Schlosser, MD, FARS
Guest Speaker: N. Louis Shipley, Harvard Business School
“Leveraging disruptive technology in a post
pandemic world”

5:30 pm - 7:00 pm
President’s Reception and Poster Reception
Tiffany Room
Saturday, October 2, 2021
8:00 am – 12:00 pm
Breakout Room A
Gold Room

Biomarkers

Moderators: Andrew Lane, MD, FARS; Victoria Lee, MD; Bruce Tan, MD

8:00 am - 8:07 am
Chronic rhinosinusitis mouse model
John Lee, MD

8:07 am - 8:14 am
Urinary leukotriene E4 as a biomarker for chronic rhinosinusitis clinical subtypes
Beau Idler, BA

8:14 am - 8:21 am
Central compartment atopic disease and allergic rhinitis have similar allergen patterns
Bianca Rullan Oliver, MD

8:21 am - 8:28 am
Biomarker model for predicting type 2 in patients diagnosed with CRS
Austin Heffernan, MD Candidate

8:28 am - 8:35 am
Tissue eosinophilia association with obesity
Lindsey Ryan, MD

8:35 am - 8:45 am
Q&A

8:45 am - 9:30 am
Panel: “Digital patient engagement for the rhinologist:
Moderator: Martin Citardi, MD, FARS
Panelists: Alexander Farag, MD, FARS; Chirag Patel, MD, FARS

9:30 am - 10:00 am
BREAK

Cystic Fibrosis

Moderators: Do-Yeon Cho, MD; Michael Kohanski, MD

10:00 am - 10:07 am
Pseudomonas isolates from CRS with CF develop increased virulence under anaerobic conditions
Do-Yeon Cho, MD

10:07 am - 10:14 am
CF olfaction before and after eluxacator-tezacaftor-ivacaftor
Daniel Bacon, BS

10:14 am - 10:21 am
Comparison of endoscopic sinus surgery timing in lung transplant patients with Cystic Fibrosis
Joseph Johnson, ScB

10:21 am - 10:28 am
Topical antibiotics in chronic rhinosinusitis: A prospective pilot study
Christopher Low, MD

10:28 am - 10:35 am
Olfactory dysfunction in people with Cystic Fibrosis
Daniel Beswick, MD, FARS

10:35 am - 10:45 am
Q&A

11:13 am - 11:23 am
Q&A

Diet and Drip

Moderators: Nicholas Rowan, MD; Angela Donaldson, MD, FARS; Edward McCoul, MD, FARS

11:23 am - 11:30 am
Otolaryngic sensory loss as a measure of frailty among older U.S. adults
Nicholas Rowan, MD

11:30 am - 11:37 am
Dietary habits and rhinitis
Darren Cheng, MS

11:37 am - 11:44 am
Diagnostic workup of patients with primary complaint of post-nasal drip
Hector Perez, MD

11:44 am - 11:51 am
Histopathologic features of chronic rhinosinusitis in diabetic patients
Vidit Talati, MD

11:51 am - 12:00 pm
Q&A

Miscellaneous Rhinology

Moderators: Alissa Kanaan, MD; Thomas Higgins, MD, FARS; Jordan Teitelbaum, MD

10:45 am - 10:52 am
Transnasal endoscopic management of frontal sinus anterior table fractures improves cosmetic quality
Natalie Derise, MD

10:52 am - 10:59 am
Clinical features and diagnoses of patients with primary complaints of facial pain
Andrea Plawecki, MD

10:59 am - 11:06 am
Outcome of immunoglobulin replacement therapy in children with rhinosinusitis
John Behnke, MD

11:06 am - 11:13 am
Contralateral sinonasal symptoms following unilateral ESS
Kevin Hur, MD
Saturday, October 2, 2021
8:00 am – 12:00 pm
Breakout Room B
Crystal Ballroom

Healthcare Economics

Moderators: Jonathan Ting, MD, FARS; Joshua Levy, MD, FARS; Kara Detwiller, MD, FARS

8:00 am - 8:07 am
Resource utilization analysis after PPSV23 vaccination in antibody deficient CRS and RABS patients
Nrusheel Kattar, MD

8:07 am - 8:14 am
Rhinology Medicare reimbursements have not been keeping up with inflation
Sina Torabi, MD

8:14 am - 8:21 am
Impact of gender on outcomes and cost in pediatric acute rhinosinusitis management
Vraj P. Shah, BS

8:21 am - 8:28 am
Impact of operative time on endoscopic sinonasal surgery
Ariel Omiunu, BS

8:28 am - 8:35 am
Procedural and geographic variation in price markup of common rhinology procedures
Rahul A. Patel, Medical Student

8:35 am - 8:45 am
Q&A

Adjunct Therapies for CRS

Moderators: Lauren Roland, MD; Christine Franzese, MD, FARS; Daniel Beswick, MD, FARS

8:45 am - 8:52 am
Long-acting implantable corticosteroid matrix for CRS: LANTERN study 6-month post-treatment outcomes
Joanne Rimmer, MBBS, MA

8:52 am - 8:59 am
The Effect of EDS-FLU on objective and subjective outcomes for patients with CRSwNP
Randall Ow, MD, FARS

8:59 am - 9:06 am
The potential for cortisol suppression with high dose mometasone irrigations
Hannah Brown, BS

9:06 am - 9:13 am
Type 2 inflammation decreases in CRSwNP after ESS with mometasone-eluting stent placement
Bruce K. Tan, MD

9:13 am - 9:20 am
Six months of aspirin therapy acts as an indicator of long-term outcomes in AERD
Siddhant H. Tripathi, BS

9:20 am – 9:27 am
Real world effectiveness of Dupilumab in CRSwNP
Yi Zhang

9:27 am - 9:35 am
Q&A

9:30 am - 10:00 am
BREAK

10:00 am - 10:45 am
Panel: ‘Omics and biomarkers: How they can impact patient care’
Moderator: Justin Turner, MD, FARS
Panelists: Bruce Tan, MD; Amber Luong, MD, PhD, FARS; Benjamin Bleier, MD, FARS

Miscellaneous Rhinology

Moderators: Kristine Smith, MD; Christian Soneru, MD; Sanjeeet Rangarajan, MD, FARS

10:45 am - 10:52 am
Practice patterns and provider satisfaction in a virtual rhinology and skull base surgery clinic
Emily Papazian, Medical Student

10:52 am - 10:59 am
Post-operative sinus polyp scale (POPS)
Dhruv Sharma, MD

10:59 am - 11:06 am
Modeling observed nasal nitric oxide levels
Dennis Shusterman, MD, MPH

11:06 am - 11:13 am
The role of extraoral taste receptors in chronic rhinosinusitis: A systematic review
Nicholas Rowan, MD

11:13 am - 11:23 am
Q&A

Complications

Moderators: Theodore Schuman, MD, FARS: Jeffrey Suh, MD, FARS; Stacey Gray, MD, FARS

11:23 am - 11:30 am
Systemic corticosteroids-related adverse outcomes in chronic rhinosinusitis with nasal polyposis
Greg Davis, MD, FARS

11:30 am - 11:37 am
Avascular necrosis and oral corticosteroid use
David Poetker, MD, FARS

11:37 am - 11:44 am
Odontogenic sinusitis causing extra-sinus complications
Jennifer Douglas, MD

11:44 - 11:51 am
Correlation of symptoms by sinus subsite
Arthur Wu, MD, FARS

11:51 am - 12:00 pm
Q&A
Saturday, October 2, 2021
8:00 am – 12:00 pm
Breakout Room C
Emerald Ballroom

Skull Base Malignancies

Moderators: Kent Lam, MD, FARS; Jose Mattos, MD; Jeremiah Alt, MD, PhD, FARS

8:00 am - 8:07 am
Treatment facility volume and esthesioneuroblastoma outcomes
Khodayar Goshtasbi, MS

8:07 am - 8:14 am
Effect of hospital safety-net burden on survival of sinonasal squamous cell carcinoma
Christopher Tseng, BS

8:14 am - 8:21 am
Sociodemographic factors in patients with esthesioneuroblastoma
Ariel Omiunu, BS

8:21 am - 8:28 am
Length of stay after surgery as a predictor of survival for sinonasal squamous cell carcinoma
Jeff Gao, BS

9:06 am - 9:16 am
Q&A

Nasal Valve, Perforation and Empty Nose

Moderators: David Jang, MD, FARS; Arthur Wu, MD, FARS; Jayakar Nayak, MD

11:15 am - 11:22 am
Temperature-controlled RF treatment of the NV for NAO: A randomized controlled trial
Stacey Silvers, Dr.

11:22 am - 11:29 am
Temperature-controlled RF treatment of nasal valve for nasal airway obstruction
William Yao, MD, FARS

11:29 am - 11:36 am
Endoscopic techniques for nasal septal perforation repair: A systematic review
Arron Gravina, DO

11:36 am - 11:43 am
Surgical repair of nasal septal perforations
Janmaris Marin, MD

11:43 am - 11:50 am
Mental health burden of empty nose syndrome
Meredith Meyer

11:50 am - 12:00 pm
Q&A

Saturday, October 2, 2021
8:00 am – 12:00 pm
Breakout Room D
Bernard's Room

Olfaction

Moderators: Carol Yan, MD; David Poetker, MD, FARS

10:30 am - 10:37 am
Population differences between COVID-19 and post-viral olfactory dysfunction: Case-control study
Nikita Chapurin, MD, MHS

10:37 am - 10:44 am
Chemesthesis compensates for decreased flavor sensation due to chemosensory dysfunction in COVID-19
Sameer Kini, MD

10:44 am - 10:51 am
Measurement of healthy utility state values in COVID-19 related anosmia
Mena Said, MD

10:51 am - 10:58 am
SriNivas Narayanan, Medical Student

10:58 am - 11:05 am
Parosmia and health utility state values for COVID-19 related olfactory loss
Sophie Jang, Research Fellow

11:05 am - 11:15 am
Q&A

Patient Demographics

Moderators: Charles Riley, MD; Naweed Chowdhury, MD; Marc Dubin, MD, FARS

8:38 am - 8:45 am
Demographic variations of participants in rhinitis clinical trials
Neil Mehta, BS

8:45 am - 8:52 am
Effect of race in epistaxis treatment
Avneet Randhawa, BS

8:52 am - 8:59 am
Characterization of biologics patients
Matthew Lelegren, MD

8:59 am - 9:06 am
Demographics in chronic rhinosinusitis subtypes
Cheng Ma, BS

11:05 am - 11:15 am
Q&A

Rhinology Malignancies

Moderators: Garret Choby, MD, FARS; Nyall London, MD, FARS

8:00 am - 8:07 pm
Nasal endoscopy and aerosol generation
Amarbir Gill, MD

8:07 am - 8:14 am
Surgical approach is associated with complication rate in sinonasal malignancy: A multi-center study
Daniel Beswick, MD, FARS
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:14 am - 8:21 am</td>
<td>Determinants of survival in sinonasal and skull base chondrosarcoma</td>
<td>Ryan Rimmer, MD</td>
</tr>
<tr>
<td>8:21 am - 8:28 am</td>
<td>Healthcare expansion and rhinologic malignancies</td>
<td>Alexandria L. Irace</td>
</tr>
<tr>
<td>8:28 am - 8:38 am</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>8:38 am - 8:45 am</td>
<td>Gender gap among rhinology and skull base surgeons</td>
<td>Patricia Johnson, MD</td>
</tr>
<tr>
<td>8:45 am - 8:52 am</td>
<td>Socioeconomic trends in rhinology and endoscopic skull base surgery in 2020</td>
<td>Sara Sun, MD</td>
</tr>
<tr>
<td>8:52 am - 8:59 am</td>
<td>Predictors of academic career placement and scholarly impact in fellowship-trained rhinologists</td>
<td>Nicholas Rowan, MD</td>
</tr>
<tr>
<td>8:59 am - 9:06 am</td>
<td>A geospatial analysis of the rhinologist workforce in the United States</td>
<td>Samir Hassanin, BA</td>
</tr>
<tr>
<td>9:06 am - 9:16 am</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>9:16 am - 9:23 am</td>
<td>Factors associated with postoperative outcomes in pituitary surgery</td>
<td>Khodayar Goshtasbi, MS</td>
</tr>
<tr>
<td>9:23 am - 9:30 am</td>
<td>Ecological momentary assessment of sinonasal outcomes</td>
<td>Victoria Lee, MD</td>
</tr>
<tr>
<td>9:30 am - 9:37 am</td>
<td>Endoscopic sinus surgery in patients with comorbidities</td>
<td>Ariel Omiunu, BS</td>
</tr>
<tr>
<td>9:37 am - 9:44 am</td>
<td>A cross-sectional analysis of patient information and education on sinusitis</td>
<td>Kolin Rubel, MD</td>
</tr>
<tr>
<td>9:44 am - 9:51 am</td>
<td>The use of SN-5 to differentiate chronic rhinosinusitis and chronic adenoiditis in children</td>
<td>Norman Orabi, MD</td>
</tr>
<tr>
<td>9:51 am - 10:00 am</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>10:00 am - 10:30 am</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>10:30 am - 10:37 am</td>
<td>Outcomes of endoscopic resection of pediatric craniopharyngiomas</td>
<td>Tapan Patel, MD</td>
</tr>
<tr>
<td>10:37 am - 10:44 am</td>
<td>Occult nodal involvement in sinonasal squamous cell carcinoma</td>
<td>Samer Elsamna, BA</td>
</tr>
<tr>
<td>10:44 am - 10:51 am</td>
<td>Race, ethnicity, and socioeconomic status in esthesioneuroblastoma outcomes</td>
<td>Rahul Sharma, BS</td>
</tr>
<tr>
<td>10:51 am - 10:58 am</td>
<td>Impact of distant metastasis in sinonasal squamous cell carcinoma</td>
<td>Samer Elsamna, BA</td>
</tr>
<tr>
<td>10:58 am - 11:05 am</td>
<td>Nasal cavity squamous cell carcinoma</td>
<td>Blaine Smith</td>
</tr>
<tr>
<td>11:05 am - 11:15 am</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>11:15 am - 11:22 am</td>
<td>Endoscopic repair of anterior encephaloceles: A cost-effective alternative to craniotomy</td>
<td>Matthew Wu, BS</td>
</tr>
<tr>
<td>11:22 am - 11:29 am</td>
<td>The role of fascia lata in complex skull base reconstruction: Emergence of a new workhorse</td>
<td>Firas Sbeih, MD</td>
</tr>
<tr>
<td>11:29 am - 11:36 am</td>
<td>False negative rate of intrathecal fluorescein in CSF leak repair</td>
<td>Jeffrey Radabaugh, MD</td>
</tr>
<tr>
<td>11:36 am - 11:43 am</td>
<td>Systematic review of olfactory preservation techniques in nasoseptal flap harvest</td>
<td>Suat Kilic, MD</td>
</tr>
<tr>
<td>11:43 am - 11:50 am</td>
<td>Endoscopic endonasal eustachian tube obliteration for cerebrospinal fluid rhinorrhea</td>
<td>Ryan Rimmer, MD</td>
</tr>
<tr>
<td>11:50 am - 12:00 pm</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>12:00 pm – 1:00 pm</td>
<td>(Heinsbergen Room) Women in Rhinology / Residents &amp; Fellows / Mentorship Lunch Program</td>
<td>Guest Speaker: Nina Shapiro, MD; Professor of Head and Neck Surgery, David Geffen School of Medicine at UCLA Director of Pediatric Otolaryngology, Mattel Children’s Hospital UCLA “Medical Communication to the Non Medical Audience: Something We All Need to Practice”</td>
</tr>
</tbody>
</table>
PROGRAM AT A GLANCE

Saturday,
October 2, 2021
1:00 pm – 4:20 pm
General Session
Crystal Ballroom

POSTERS

Poster A001
70-degree endoscope in maxillary antrostomy
Firas Hentati, MD

Poster A002
Acute exacerbations, a CRS patient’s perspective
Katie Phillips, MD

Poster A003
Balloon septoturbinitomy
Alexander Farag, MD, FARS

Poster A004
Baseline blood eosinophil level is not a biomarker for CRSwNP severity or response to dupilumab
Claudia Bachert, MD

Poster A005
Caffeine consumption and rhinitis
Michael DeBakey, MS

Poster A006
Canine endoscopic sinonasal surgery
Charles Riley, MD

Poster A007
CFTR mutations in patients with CRS: A systematic review
Michael Yong, MD, MPH, MBA

Poster A008
Chronic rhinosinusitis with nasal polyposis patients receiving monoclonal antibody therapy
Mohamed Babi, MD

Poster A009
Differences in clinical presentation for patients with frontal sinus mucoceles
Dhruv Sharma, MD

Poster A010
Dupilumab improves sense of smell in CRSwNP patients with 0, 1, 2, or ≥3 prior surgeries
Joaquim Mullol, MD, PhD

Poster A011
Endoscopic retro-orbital fistula repair
Yu Hsuan Lin, MD

Poster A012
Endoscopic removal of a nasal septal pleomorphic adenoma: A case report and literature review
Hannah Case

Poster A013
ENT visits and procedures in COVID recovered
Dennis Tang, MD

Poster A014
Epistaxis in CPAP patients
Theodore Klug, MD, MPH

Poster A015
Impact of asthma status on outcomes and cost in pediatric acute rhinosinusitis management
Vraj Shah, BS

Poster A016
Impact of asthma status on outcomes and cost in pediatric nasal polyp management
Vraj Shah, BS

Poster A017
Impact of comorbidities on 30-day outcomes after TSS
Sudeepi Vedula, BS

Poster A018
Impact of Cystic Fibrosis on outcomes and cost in pediatric nasal polyp management
Vraj P. Shah, BS

Poster A019
Incidence and implications of HPV tumor status in non-squamous cell carcinoma sinonasal malignancies
Jason Lee, MD

Poster A020
Internal carotid artery pseudoaneurysm and blow-out secondary to chronic invasive fungal sinusitis
Camilo Reyes, MD, FARS

Poster A021
Intranasal budesonide delivered by nasal nebulizer compared to a sinus rinse
Marc Nagel, H.BSc

Poster A022
MicroRNA-29a promotes the allergic rhinitis by down-regulating FOS
Zhiyuan Tang, PhD

Poster A023
Nasal nitric oxide as a biomarker in the diagnosis and treatment of sinonasal inflammatory diseases
Matthew Lelegren, MD

Poster A024
Nasopharyngeal pedicled pituitary mass: A case report
Madison Colcord, BS

All information was taken from the original abstract submission

WITHDRAWN
| Poster A025 | National analysis on the inpatient management of chronic rhinosinusitis in the pediatric population | Bryan Le, BS |
| Poster A026 | Navigation-assisted intradural skull base surgery | Ariel Omiunu, BS |
| Poster A027 | Performance and safety of image guided sinus dilation system in revision endoscopic sinus surgery | Joseph Han, MD, FARS |
| Poster A028 | Preoperative laboratory testing in low risk ambulatory ESS | Sudeepti Vedula, BS |
| Poster A029 | Prevention of frontal sinus ostium stenosis after modified Lothrop (Draf III) frontal sinus surgery | Yasuyuki Hinohira, MD, PhD |
| Poster A030 | Progressive improvement of severe CRSwNP with dupilumab: Post-hoc analysis of two Phase 3 studies | Claus Bachert, MD |
| Poster A031 | Qualitative study of disease control in CRS | Katie Phillips, MD |
| Poster A032 | Respiratory epithelial adenomatoid hamartoma in a 76-year-old female | Haroon Alam |
| Poster A033 | Seropositivity to microbial proteins in CRS using high throughput microarray technology | Devyani Lal, MD, FARS |
| Poster A034 | Severity of loss of smell and paranasal sinus opacification | Stella Lee, MD |
| Poster A035 | Shortening the learning curve: Virtual reality rhinoplasty | Janmaris Marin Fermin, MD |
| Poster A036 | Sociodemographic disparities and patterns of care in sinonasal adenocarcinoma | Sudeepti Vedula, BS |
| Poster A037 | The impact of PROPEL® Implant during sinus surgery on healthcare resource utilization | Kathleen Mortimer, ScD, MPH |
| Poster A038 | Topical anesthesia in nasal endoscopy: To use or not to use? | Prithwijit Roychowdhury, BS |
| Poster A039 | Treatment of recurrent frontoethmoid mucocele | Lindsey Ryan, MD |
| Poster A040 | Unilateral Vidian main neurectomy on moderate to severe allergic rhinitis | Zhiyuan Tang, PhD |
| Poster A041 | Vibration therapy in sinonasal disease | Pooya Roozdar, MD, MPH |
| Poster A042 | Woakes' Syndrome: A case series | Alexander Dickie, MD |

(withdrawn)
Exhibitors

3-D MATRIX, Inc. – Booth 19
1234 Chestnut Street, Suite 205
Newton, MA 02464
Phone: 781-373-9020
Email: info@3dmatrix.com
Website: www.3dmatrix.com
Twitter: https://twitter.com/3dmatrixNA

3-D Matrix, Inc. is proud to introduce PuraSinus to the US market. A game-changing product based on technology invented at MIT for use in various surgeries is now FDA approved for sinus surgery. PuraSinus is indicated for hemostasis, adhesion-prevention and wound healing. PuraSinus nanofiber peptides self-assemble on contact with physiological fluid to develop a synthetic matrix forming a mechanical barrier to control bleeding, maintain moisture on exposed mucosa, aiding the natural healing process and preventing the formation of post-operative adhesions. PuraSinus sets a new standard for product consolidation all the while enhancing clinical performance and patient outcomes.

ACCLARENT – Showcase S1
31 Technology Drive
Irvine, CA 92618
Phone: 877-775-2789
Email: customerservice@acclarent.com
Website: www.acclarent.com
Twitter: https://twitter.com/Acclarent_US
Linkedin: https://www.linkedin.com/company/acclarent/

Acclarent, Inc., part of Johnson & Johnson Medical Devices Companies, is aligned around a singular focus to free patients to live better lives be designing, developing, and commercializing medical devices that address conditions affecting the ear, nose, and throat. For more than a decade, Acclarent has led the field in delivering innovative technologies to ENT surgeons. For more information, visit www.acclarent.com.

ADVANCED RX COMPOUNDING PHARMACY – Booth 18
414 Commerce Drive, Suite 100
Fort Washington, PA 19034
Phone: 484-681-5756; Fax: 866-308-3832
Email: accounts@advancedrx.net
Website: www.advancedrx.net

Advanced RX is an ENT only compounding pharmacy specializing in steroid, antibiotic, and antihistamine nasal rinses at affordable prices.
Exhibitors

AERIN MEDICAL – Showcase S3
232 E. Caribbean Drive
Sunnyvale, CA 94089
Phone: 433-484-8237
Email: info@aerinmedical.com
Website: www.aerinmedical.com
Facebook: https://www.facebook.com/aerinmedical/
Twitter: https://twitter.com/AerinMedical
Linkedin: https://www.linkedin.com/company/aerin-medical

Aerin’s temperature-controlled radio frequency (RF) platform is clinically effective, non-invasive, and utilizes technology indicated to improve nasal obstruction and chronic rhinitis conditions.

- VivAer® addresses nasal airway obstruction by treating the lateral nasal wall, septal tissue and inferior turbinate.
- RhinAer® comprehensively addresses chronic rhinitis by treating the posterior nasal nerve and inferior turbinate.

Unlike traditional RF, the Aerin® technology platform automatically adjusts its power output to maintain target temperature for therapeutic benefit while sparing surround tissue. VivAer and RhinAer fit seamlessly in both office and OR settings. The products are backed by robust clinical evidence and have been used in over 35,000 patients to date.

ALK-Abelló, Inc. – Booth 17
1700 Royston Lane
Round Rock, TX 78664
Phone: 512-251-0037; Fax: 512-251-5882
Email: paul.ulrich@alk.net
Website: www.alk.net/us
Facebook: https://www.facebook.com/ALK-US-111100307007981
Twitter: https://twitter.com/us_alk

ALK, Inc. is a global, research-driven pharmaceutical company focused on the diagnosis and treatment of allergies. Our products and services include SLIT-Tablets, Allergy Extracts, Penicillin Allergy Skin Testing, a Ciprofloxacin Otic Suspension, Diagnostic Controls, Skin Testing Systems, Sterile Empty Vials, Diluents, Syringes, Trays, and Patient Education Materials.

C2Dx – Booth 24
555 E. Eliza Street, Suite A
Schoolcraft, MI 19087
Phone: 888-902-2239; Fax: 269-204-2480
Email: Quintree@c2dx.com
Website: www.Quintree.com

Quintree is telehealth software focused on doctor-to-doctor collaboration, allowing you to consult remotely utilizing equipment you already have. Quintree is being sold though C2Dx – a medical device company that invests in and refines the delivery of valuable, niche products to propel their growth and accessibility worldwide. Founded in early 2019 by industry experts, C2Dx is committed to providing leading medical products and superior customer service while continually evolving to ensure that healthcare providers have the devices and technology they need.
Exhibitors

DUPIXENT – Booth 11
Website:  www.dupixenthcp.com/virtualexperience
Email:  medinfo@regeneron.com

DUPIXENT® (dupilumab)

DUPIXENT® is currently approved in the US for three indications. Please visit our virtual booth at http://www.dupixenthcp.com/virtualexperience to learn more!

©2021 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. DUPIXENT® is registered trademark of Sanofi Biotechnology.

Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation around the globe.

Regeneron
Regeneron is a leading biotechnology company that invents medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists our unique ability to repeatedly and consistently translate science into medicine has led to multiple FDA-approved treatments, almost all of which were homegrown in our laboratories.

GSK – Booth 16
5 Moore Drive
Research Triangle Park, NC  27709
Phone:  1-888-825-5249

Website:  www.gsk.com
www.contactus.gsk.com

GSK is a science-led global healthcare company with a special purpose. We research, manufacture, and make available a broad range of medicines, vaccines and consumer healthcare products.

HEMOSTASIS, LLC. – Showcase S5
5000 Township Parkway
St. Paul, MN 55110
Phone:  651-233-2074; Fax:  651-855-1465
Email:  Customerservice@hemostasisllc.com
Website:  www.hemostasisllc.com/

A leader in hemostat dressings and intranasal splints. We are excited to introduce our newest technology, Vectra drug delivery micro-sponge. Please stop by our booth to discuss the benefits Vectra can bring to your practice along with our PosiSepX and a variety of hemostat and wound healing offerings.
Exhibitors

INTERSECT ENT – Showcase S2
1555 Adams Drive
Menlo Park, CA 94025
Phone: 650-641-2100
Email: info@intersectENT.com
Website: www.IntersectENT.com
Twitter: https://twitter.com/intersectent
LinkedIn: https://www.linkedin.com/company/intersect-ent

Intersect ENT is a medical technology company dedicated to advancing the treatment of ear, nose, and throat (ENT) conditions through evidence-based innovation. We provide treatments for people with chronic sinusitis, an inflammatory sinus condition that has been shown to substantially reduce quality of life. Our core technology is based upon a bioabsorbable drug release platform and we have recently expanded our offerings to include an innovative navigation and balloon system. The family of implants is designed to provide mechanical support and localized drug delivery, while our newly expanded portfolio will extend our offerings to help patients across the sinusitis care continuum.

KARL STORZ ENDOSCOPY-AMERICA, INC. – Booth 8
2151 E. Grand Avenue
El Segundo, CA 90245
Phone: 800-421-0837
Email: communications@karlstorz.com
Website: https://www.karlstorznetwork1.com/ent
LinkedIn: https://www.linkedin.com/company/karl-storz-endoscopy

KARL STORZ enables early diagnosis and early intervention to your support patient outcome, physician satisfaction and help lower cost of care. Stop by our booth to learn how we can enable anywhere care in your practice. Visit https://www.karlstorznetwork1.com/ent to see more now.

MEDTRONIC – Booth 14
710 Medtronic Pkwy
Minneapolis, MN 55432
Phone: 763-514-4000; Fax: 763-514-4879
Email: RS.ENTMarketing@medtronic.com
Website: www.medtronic.com
Facebook: https://www.facebook.com/Medtronic
Twitter: https://twitter.com/Medtronic
LinkedIn: https://linkedin.com/company/medtronic

Patients are at the center of everything we do—and we believe medical technology can play an even greater role in improving people’s lives. Join us in our commitment to take healthcare Further, Together. Be inspired at medtronic.com
Exhibitors

MICROGENDX – Booth 32
5826 Hoffner Avenue
Suite 1004
Orland, FL 32822
Phone: 407-204-1400; Fax: 407-204-1401
Email: info@microgendx.com
Website: www.microgendx.com
Facebook: www.facebook.com/microgendx
Twitter: www.twitter.com/microgendx
LinkedIn: https://www.linkedin.com/company/microgendx

MicroGenDX provides physicians and their patients with the most advanced molecular based microbial testing available. Through the utilization of Next Generation DNA Sequencing (NGS), MicroGenDX identifies causative microbes within patient samples and matches DNA sequence codes of 50,000+ microbial species with 99.9% accuracy. This technology provides physicians with the precise information needed to make confident treatment decisions based on solid DNA evidence. This knowledge ensures targeted antibiotic selection leading to superior patient outcomes.

MODERNIZING MEDICINE – Booth 27
4850 T-Rex Avenue, Suite 200
Boca Raton, FL 33431
Phone: 561-880-2998
Website: www.modmed.com
Twitter: www.twitter.com/modmed
Facebook: www.facebook.com/ModernizingMedicine/
LinkedIn: https://www.linkedin.com/company/modernizing-medicine

The modmed® Otolaryngology suite is a cloud-based, electronic health records (EHR) and practice management (PM) system designed to adapt to each doctor’s style of practice, remembering preferences and automatically suggesting documentation and billing codes. When used on a tablet, EMA®, our EHR, works seemlessly with our other products and services including PM, revenue cycle management, Analytics, modmed Telehealth, modmed Pay, patient engagement tools and more. With easy-to-use mobile touch screen capabilities, our intuitive, all-in-one solution helps enteralogists save precious time and allows them to focus on what’s important - improving patient outcomes.

NEILMED PHARMACEUTICALS INC. – Booth 29
601 Aviation Blvd.
Santa Rosa, CA 95403
Phone: 707-525-3784; Fax: 707-525-3785
Email: tradeshows@neilmed.com
Website: www.neilmed.com

The mission of the company is to create and maintain safe, affordable, and effective products to sustain long-term growth and create drug-free and effective Sinus, Ear, First Aid, and Baby care devices for millions of consumers worldwide. Please visit the website www.neilmed.com for more details.
Exhibitors

OLYMPUS AMERICA INC. – Booth 20
800 West Park Drive
Westborough, MA 01581
Phone: 800-401-1086
Email: louis.lariviere@olympus.com
Website: https://medical.olympusamerica.com/
Twitter: https://twitter.com/OlympusMedUS
Instagram: https://www.instagram.com/olympusamericas/

For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping to detect, prevent and treat disease. Olympus’ ENT business uses innovative capabilities to deliver diagnostic and therapeutic solutions to Otolaryngologists practicing Rhinology. Our capabilities in visualization – including both 4K and HD solutions – enable surgeons to have the best endoscopic view possible. Olympus therapeutic solutions are found in all sites of care – hospital operating rooms, ambulatory surgical centers, and in the office. Olympus’ Rhinology portfolio includes the DIEGO® ELITE Multidebrider, Celon Elite radiofrequency system for turbinate reduction, and the recently launched ChitoZolve Dissolvable Chitosan Intranasal Splint. And all your surgical images and videos can be securely captured, stored and shared across the enterprise using Olympus content management solutions such as nCare and Vaultstream.

OPTINOSE – Booth 7
1020 Stony Hill Rd., Suite 300
Yardley, PA 19067
Phone: 267-364-3500
Email: Kristen.miller@optinose.com
Website: www.optinose.com and www.xhance.com

Optinose is proud to be a sponsor of the ARS 10th Annual Summer Sinus Symposium. Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. See how Exhalation delivers medicine in a different way. Learn more about deposition with XHANCE® (fluticasone propionate) nasal spray 93 mcg visiting our booth or www.xhancehcp.com.

STRYKER ENT
3600 Holly Lane N, Suite 40
Plymouth, MN 55447
Phone: 763-463-1595
Website: https://ent.stryker.com
Facebook: https://www.facebook.com/StrykerENT/?view_public_for=103026761734619
LinkedIn: https://www.linkedin.com/showcase/stryker_ent

At Stryker, everything starts with our mission - Together with our customers we are driven to make healthcare better. We work each and every day to deliver on that mission by providing innovative solutions that simplify the complex, address the unmet needs of your patients, and offer you the flexibility to deliver care in your preferred site of service. Our unique ENT portfolio expands your treatment options for your patients with chronic rhinitis, chronic sinusitis, Eustachian tube dysfunction and nasal airway obstruction. With Stryker, you gain access to a complete suite of solutions to help make your vision of patient care a reality. From room infrastructure to suction and filtration, technology to training, reimbursement tools to patient education, Stryker is here to help. The control you need. The flexibility you want. The experience your patients deserve. Care without compromise.
Exhibitors

XORAN TECHNOLOGIES – Booth 26
5210 S. State Road
Ann Arbor, MI  48108
Phone:  734-418-5133
Email:  info@xorantech.com
Website:  www.xorantech.com
LinkedIn:  https://www.linkedin.com/company/xoran-technologies

Xoran Technologies is the pioneer of low-dose radiation, cone beam CT scanners for use in-office and operating rooms.  The flagship product, MiniCAT, is an in-office, point-of-care imaging solution for ENT and Allergy physicians. Xoran provides 3-dimensional low dose imaging – with workflow designed for simplicity and ease of use.
Meeting WIFI

Network: Biltmore Special Events
Pass Code: welcometola20

Download the Mobile App Now!

https://crowd.cc/s/44hQM

Scan this code with a QR reader to easily download the app.
Contact: Wendi Perez, ARS Executive Administrator
Tel: 973-545-2735, Ext. 4105  Email: wendi@american-rhinologic.org

american-rhinologic.org
Twitter: @amrhinosociety  Facebook: @americanrhinologicsoctety  Instagram: amrhinosociety